BRAF and metastatic colorectal cancer: Another example was that patient-derived organoids with BRAFV600E mutation exhibited dramatically reduced viability but no differences in apoptosis after the exposure of the BRAF inhibitor vemurafenib in comparison with the organoids with no mutations in BRAF gene, which was consistent with the ineffectiveness of monotherapy with BRAF inhibitors in metastatic colorectal cancer [26].